期刊文献+

Ki67、Survivin蛋白在原发性肝细胞癌组织中的表达及临床意义

Expression and clinical significance of Ki67,Survivin protein in hepatocellular carcinoma tissue
下载PDF
导出
摘要 目的探讨细胞核增殖抗原(Ki67)、凋亡抑制蛋白Survivin在原发性肝细胞癌(HCC)发生、发展中的作用。方法选择我院手术切除的HCC组织标本60份(肿瘤组),正常肝组织20份(正常组),采用免疫组化SP法检测两组中Ki67、Survivin蛋白表达,分析两者相互间及与HCC临床病理参数的相关性。结果肿瘤组Ki67、Sur-vivin蛋白表达阳性率明显高于正常组,P<0.01;Ki67、Survivin在HCC中的表达均与包膜侵犯、癌栓形成及肿瘤转移有关,P<0.05;HCC组织中Ki67与Survivin表达呈正相关。结论 Ki67与Survivin联合检测可为HCC的诊断和治疗提供依据。 Objective To investigate the role of nuclear proliferation antigen (Ki67) and inhibitor of apoptosis protein Survivin in the occurrence and development of hepatocellular carcinoma (HCC). Methods The expression of Survivin and Ki-67 was examined and compared by S-P immunohistochemistry in normal liver tissue of 20 cases ( normal group) and HCC tissue specimens of 60 cases (tumor group), the relationship between Ki67 and Survivin expression and the clinical pathology features of the HCC patients were analyzed. Results The positive rates of Ki67 and Survivin expression in tumor group were both significantly higher than those in normol group ( both P 〈 0.01 ). The Ki67 and Survivin expression in HCC were both correlated with the envelope invasion, progression of tumor thrombus and metastasis; There expression of Ki67 and Survivinwas was positively correlated with each other. Conclusion Co-detection of Survivin and Ki67 can supply certain evidence on diagnosis and treatment of HCC.
作者 刘起胜
出处 《山东医药》 CAS 2012年第35期53-54,共2页 Shandong Medical Journal
基金 湖南省教育厅科学研究资助项目(11C0974)
关键词 肝细胞癌 细胞核增殖抗原 凋亡抑制蛋白 免疫组织化学 hepaticcellular cancer Ki67 Survivin immunohistochemistry
  • 相关文献

参考文献8

二级参考文献33

  • 1贾学玲,高云荷,张煦.子宫内膜增生及内膜癌中PTEN、Ki-67蛋白的表达[J].临床与实验病理学杂志,2003,19(2):152-155. 被引量:19
  • 2Liu X,Erikson R L. Activation of Cdc2/eyclin B and inhibition of centrosome amplification in cells depleted of plk1 by siRNA [J]. Proc Natl Acad Sci, 2002,99(13) :8672-8676.
  • 3Smith M R,Wilson M L, Hamanaka R, et al. Malignant transformation of mammalian ceils initiated by constitutive expression of the polo-like kinase[J]. Biochem Biophys Res Commun, 1997,234(2) :397-405.
  • 4Elia A E,Rellos P, Haire L F, et al. The molecular basis for phosphodependent substrate targeting and regulation of plks by the Polo-box domain[J]. Cell, 2003,115(1):83-95.
  • 5Takahashi T, Sano B, Nagata T, et al. Polo-like kinase 1 (plk1) is overexpressed in primary colorectal cancers[J]. Cancer Sci, 200a, 04(2) : 148-152.
  • 6Weichert W, Denkert C, Schmidt M, et al. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma [J]. BrJ Cancer, 2004,90(4):815-821.
  • 7Tokumitsu Y, Mori M, Tanaka S, et al. Prognostic significance of polo-like kinase expression in esophageal carcinoma [J]. Int J Oncol, 1999,15(4):687-692.
  • 8Wolf G, Hildenbrand R, Schwar C, et al. Polo-like kinase: A novel marker of proliferation: correlation with estrogenrecep tor expression in human breast cancer[J]. Pathol Res Pract, 2000,196(11) : 753-759.
  • 9Kneisel L,Strebhardt K, Bernd A, et al. Expression of pololike kinase (PLK1) in thin melanomas: a novel marker of metastatic disease[J]. J Cutan Pathol, 2002,29(6):354-358.
  • 10Herrera R,Sebolt-Lepold J S. Unraveling the complexities of the Raf/MAP kinasc pathway for pharmacological intervention[J]. Trends Mol Med, 2002,8(4) :S27-31.

共引文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部